Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012)
Johnson & Johnson (JNJ) posted Land & Improvements of $754.0 million for Q1 2012, up 2.17% sequentially from $738.0 million in Q1 2011, and up 2.17% YoY from $738.0 million in Q1 2011.
Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012) Analysis & Trends
Johnson & Johnson (JNJ) has 2 years of Land & Improvements data on file, last reported at $754.0 million in Q1 2012.
- Quarterly Land & Improvements rose 2.17% year-over-year to $754.0 million in Q1 2012, while the trailing twelve-month figure through Jan 2012 was $754.0 million (up 2.17% YoY) and the FY2012 annual result came in at $754.0 million, up 2.17% from the prior year.
- Land & Improvements advanced to $754.0 million in Q1 2012 per JNJ's latest filing, from $738.0 million in the prior quarter.
- The five-year high for Land & Improvements was $754.0 million in Q1 2012, with the low at $738.0 million in Q1 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2012 | 754.00 Mn |
| Jan 2, 2011 | 738.00 Mn |